Pao Group Inc. (OTCMKTS:PAOG) Expanding Its Nutraceutical Revenue Streams
April 14 2021 - 11:03AM
InvestorsHub NewsWire
April 14, 2021 -- InvestorsHub NewsWire -- via
Facts About CBD - Ward Sport
Pao Group Inc. (OTCMKTS:PAOG) has
announced that it expects revenue
expansion this
year from CBD neutraceuticals. The company published an online and
multimedia presentation showing its CBD nutraceutical development
expansion plans. Most importantly, the presentation includes its
strategy engagements with Puration Inc. (OTCMKTS:PURA),
Alkme Holdings Inc. (OTCMKTS:ALKM),
and North American Cannabis Holdings Inc. (OTCMKTS:USMJ).
Pao Group acquired RespRx in
2020
Last year,
the company completed the acquisition of RespRx, a cannabis
medication currently under development for the treatment of Chronic
Obstructive Pulmonary Disorder derived through a patented marijuana
extraction method. According to WHO, around 65 million globally
have moderate to severe COPD, with around three million deaths
reported each year. COPD treatment market is estimated to be around
$5 billion in the US and $11 billion
globally.
Notably,
GW Pharmaceuticals has set the base for cannabis treatment and
recently was valued at $7.2 billion. The patented extraction method
inventor Frederic Ferri said that doctors researching their
feedback have given feedback regarding the feedback’s superiority
compared to those of GW
Pharmaceuticals.
Pao Group
recently entered an
engagement with
Veristat Inc. to assist in advancing its novel CBD extract for COPD
treatment towards an IND with the US FDA. The company
recognizes and acknowledges that pharmaceutical development will be
a capital intensive and long-term undertaking. As a result, Pao
Group is pursuing complementary business initiatives that can
generate revenue in the near term and contribute to funding the
RespRx development in the long
term.
Pao Group expanding nutraceutical
development
Besides
efforts to develop COPD treatment, the company also announced that
it has engaged Puerto Rico Consortium for Clinical Investigation to
help it develop novel CBD extract into nutraceutical products for
the care of individuals experiencing issues related to COPD. Pao
Group management is confident that CBD extraction knowledge base
and experience can help pursue the development of more
neutraceuticals.
As a
result, doing so will expand the company’s overall near-term
revenue potential. The company expects revenue this year from
neutraceuticals following the recent sales agreement with Puration.
The company expects revenue of $50,000 each quarter.
Source - https://factsaboutcbd.org/pao-group-inc-otcmktspaog-expanding-its-neutraceutical-revenue-streams-4319
North American Cannabis (CE) (USOTC:USMJ)
Historical Stock Chart
From Apr 2024 to May 2024
North American Cannabis (CE) (USOTC:USMJ)
Historical Stock Chart
From May 2023 to May 2024